A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Summary

This randomized, double-blind, placebo-controlled study will assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in patients with type 2 diabetes mellitus. Patients will be randomized to receive either RO5095932 subcutaneously once weekly or placebo for 4 weeks (part 1) or 6 weeks (part 2), in addition to their current stable doses of metformin.

Timeline

Start

2009-06

Primary completion

2010-10

Completion

2010-10

Drugs

Indications